444 related articles for article (PubMed ID: 36110399)
41. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
42. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
43. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
Otter SJ; Chatterjee J; Stewart AJ; Michael A
Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
45. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
Nishimura CD; Pulanco MC; Cui W; Lu L; Zang X
Trends Mol Med; 2021 Mar; 27(3):207-219. PubMed ID: 33199209
[TBL] [Abstract][Full Text] [Related]
46. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
47. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
Jiang Y; Zhao X; Fu J; Wang H
Front Immunol; 2020; 11():339. PubMed ID: 32226426
[TBL] [Abstract][Full Text] [Related]
48. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
Munari E; Mariotti FR; Quatrini L; Bertoglio P; Tumino N; Vacca P; Eccher A; Ciompi F; Brunelli M; Martignoni G; Bogina G; Moretta L
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066087
[TBL] [Abstract][Full Text] [Related]
49. Effect of immunotherapy on the immune microenvironment in advanced recurrent cervical cancer.
Chen R; Yang W; Li Y; Cheng X; Nie Y; Liu D; Wang H
Int Immunopharmacol; 2022 May; 106():108630. PubMed ID: 35189471
[TBL] [Abstract][Full Text] [Related]
50. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Xiong W; Gao Y; Wei W; Zhang J
Trends Cancer; 2021 Sep; 7(9):837-846. PubMed ID: 33903073
[TBL] [Abstract][Full Text] [Related]
51. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
52. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
Skafi N; Fayyad-Kazan M; Badran B
Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
[TBL] [Abstract][Full Text] [Related]
53. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
[TBL] [Abstract][Full Text] [Related]
54. [Specific immunotherapies in the treatment of cancers].
Denis H; Davoine C; Bermudez E; Grosjean G; Schwager M; Ifrah N; Dahan M; Negellen S
Bull Cancer; 2019 Jan; 106(1):37-47. PubMed ID: 30638899
[TBL] [Abstract][Full Text] [Related]
55. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
56. Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract][Full Text] [Related]
57. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
58. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
59. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
60. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
